Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.68 |
| ▸ | RAB9A | P51151 | 13/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.68 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.56 |
| ▸ | RELA | Q04206 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951197 | 0.88 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL5017000 | 0.85 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1820681 | 0.81 | SMN1; SMN2 (0.64) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL30195363 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1821021 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL30073965 | 0.80 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL3112891 | 0.80 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL14881038 | 0.78 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1820826 | 0.77 | DHODH (0.59) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL1820740 | 0.77 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
| EP-1638556-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000301-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021478-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | NPC1 421/4885RAB9A 1479/4885SMN1; SMN2 3860/4885 |
| US-20040266845-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | NPC1 237/4885RAB9A 900/4885SMN1; SMN2 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.